Piper Jaffray analyst Tyler Van Buren said Incyte reported positive updates for the topical ruxolitinib programs in vitiligo and atopic dermatitis at the World Congress of Dermatology, which he said "further reinforce" the enthusiasm he has about the product candidate. In the data presented at the meeting, ruxolitinib demonstrated "impressive" activity in vitiligo and "solid efficacy" in atopic dermatitis out to 12 weeks, said Van Buren, who thinks the drug could generate over $1B in global sales by the late 2020s for its combined eventual indications. He keeps an Overweight rating on Incyte shares.